News

Sanofi finds M&A fix for its multiple itches
The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...
Fierce Pharma1d
With Opella proceeds burning a hole in its pocket, Sanofi snaps up Blueprint for $9.1B
With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...
Medical Dialogues2h
Sanofi Rilzabrutinib gets USFDA orphan drug designation for sickle cell disease
Paris: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for rilzabrutinib, a novel, ...
Fierce Biotech1d
Sanofi pays $15M for another STAT6 degrader from fruitful Nurix collab
Sanofi paid $55 million to partner with the biotech in 2019 and handed over a further $22 million to expand the collaboration ...
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...
Fierce Pharma21h
ASCO: Sanofi shows investigational Sarclisa SC, delivered by on-body device, measures up to its IV formulation
Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing ...
Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials
Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...
Sanofi to buy US blood disorder drugmaker for up to $9.5bn
Sanofi will buy the US maker of the world’s only approved treatment for a debilitating rare blood disorder for up to $9.5bn, as it seeks to boost its immunology medicine pipeline.